Dermatology Times Spot Test: May 24, 2025

Dermatology Times presents: Spot Test!

Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology.

This week, we’ll focus on the US FDA's approval of roflumilast (Zoryve; Arcutis) foam 0.3%, a steroid-free topical treatment for plaque psoriasis of the scalp and body in adults and adolescents aged 12 and older.

Do you have a set of quiz questions to share? Contact editor Emma Andrus at eandrus@mjhlifesciences.com to contribute!

References

1. Arcutis’ Zoryve (roflumilast) topical foam 0.3% approved by US FDA for the treatment of plaque psoriasis in adults and adolescents ages 12 and older. News release. Arcutis Biotherapeutics. Published May 22, 2025. Accessed May 22, 2025. https://www.arcutis.com/arcutis-zoryve-roflumilast-topical-foam-0-3-approved-by-u-s-fda-for-the-treatment-of-plaque-psoriasis-in-adults-and-adolescents-ages-12-and-older/
2. Gooderham MJ, Alonso-Llamazares J, Bagel J, et al. Roflumilast foam, 0.3%, for psoriasis of the scalp and body: The ARRECTOR phase 3 randomized clinical trial. JAMA Dermatol. Published online May 07, 2025. doi:10.1001/jamadermatol.2025.1136